Slide 1: Transforming cancer care with a liquid biopsy based on a simple blood test
Transforming cancer care with a liquid biopsy based on a simple blood test Presentation at Proactive One2One Virtual Forum Andrew Newland and Ian Griffiths 20 May 2021 Analysis of circulating tumor cells (CTCs) can revolutionise cancer care addressing flaws in patient care exposed by COVID-19
Slide 2: Legal disclaimer
LSE AIM: AGL OTCQX: ANPCY Legal disclaimer This presentation has been prepared by ANGLE plc (the “Company”). By attending this presentation and/or reviewing the slides you agree to be bound by the following conditions. The presentation slides which follow this notice and the oral presentation of whi
Slide 3: Liquid biopsy - improving patient outcomes and reducing healthcare costs
Liquid biopsy - improving patient outcomes and reducing healthcare costs Parsortix® cassette “ANGLE’s mission is to enable personalised cancer care by providing the complete picture of the patient’s cancer from a simple blood test. Product-based solution for simple, effective, affordable repeat test
Slide 4: Parsortix liquid biopsy addresses flaws in standard of care
Parsortix liquid biopsy addresses flaws in standard of care • Existing approach: solid tissue biopsy – clinicians cut out tumor and analyse the cancer cells – difficulty in accessing some tumors such as pancreatic, lung, brain, liver and bone cancers – repeat tissue biopsy problematic, expensive and
Slide 5: Total addressable market > US $100 billion p.a.
Total addressable market > US $100 billion p.a. Current focus Medium term Longer term Detection of Therapy Assessing Remission Early screening “Successful validation of our approach in future clinical studies cancer in high selection treatment monitoring for cancer could revolutionize clinical manag
Slide 6: CTCs provide the complete picture for repeat biopsies
CTCs provide the complete picture for repeat biopsies Tissue ctDNA CTCs CTC clusters CTC cultures Clinicians cut out Fragments of dead Harvest intact 80x greater Growth of cancer part of the tumor cells living cancer cells metastatic outside patient and analyse cancer (CTCs) potential in a cells Par
Slide 7: Parsortix capturing and harvesting living cancer cells
Parsortix capturing and harvesting living cancer cells Plan view Platform technology The Parsortix system harvests cancer cells from blood based on their larger size and lack of deformability. Inlet Outlet Other cells can be captured: • megakaryocytes (frequency may relate to cancer) • fetal cells f
Slide 8: Parsortix system patent protected worldwide
Parsortix® system patent protected worldwide • Stepped, microscale cell separators for fluid flow and cell separation • Manufactured under ISO 13485:2016 quality control • Scalable business with third party manufacture • 26 granted patents: United States, Europe, China, Australia, Canada, Japan, Mex
Slide 9: Animation showing operation of Parsortix cassette
Animation showing operation of Parsortix cassette © ANGLE plc 2021 9
Slide 10: Patient blood flowing in Parsortix cassette
Patient blood flowing in Parsortix cassette © ANGLE plc 2021 10
Slide 11: Growing body of evidence; leveraged R&D strategy identifying new applications
Growing body of evidence Leveraged R&D strategy identifying new applications Research use pricing Instrument Cassette • Translational research market US $50 million p.a. Price1 $50,000 $100 • FDA clearance expected to help Parsortix become the CTC system of choice Cost $15,6002 $15 Margin 69% 85% •
Slide 12: Prospect of FDA clearance during H2 CY21
Prospect of FDA clearance during H2 CY21 • Seeking first ever FDA clearance for a device to harvest cancer cells from patient blood for subsequent analysis • Positive results from clinical and analytical studies with four leading US cancer centres participated – University of Texas MD Anderson Cance
Slide 13: Clinical laboratories established in US and UK
Clinical laboratories established in US and UK • Pharma services and initial clinical services • Offer new tests: – epithelial, EMTing, mesenchymal CTCs and clusters – ER/PR/HER2 application – PD-L1 immunotherapy – ovarian cancer test (pelvic mass assay) • Accelerator for Parsortix LDT clinical appl
Slide 14: Ovarian cancer pelvic mass triage test clinical study in progress
Ovarian cancer pelvic mass triage test clinical study in progress • Over 750,000 women p.a. diagnosed with pelvic mass in the US alone • Over 200,000 women p.a. in US alone have surgery for pelvic mass with advance diagnosis of ovarian cancer a critical unmet medical need “The next generation ANGLE
Slide 15: Near term commercialisation plan
Near term commercialisation plan Leading cancer centres with original research and peer-reviewed publications using ANGLE’s Parsortix system (selection) • Expanding pharma services business • Prospect of FDA clearance during H2 CY21* • Ovarian cancer headline results expected Q4 CY21 • Seeking to la
Slide 16: ANGLE plc contact details
ANGLE plc ANGLE Europe Ltd 10 Nugent Road Surrey Research Park Guildford GU2 7AF United Kingdom ANGLE North America Inc 5100 Campus Drive Suite 120 Plymouth Meeting PA 19462 USA ANGLE Biosciences Inc 50 Ronson Drive, Suite 105 Toronto Ontario M9W 1B3 Canada www.angleplc.com 16